



## 14 Best Biotech Company Total Market Value: \$1 Trillion

**15.6 billion** (7.8B people x 2 dose/yearly) **vaccines** in needed to eliminate pandemic 3-4 years at least.

Also, **SARS Co-2 gets mutations** on its genome (RNA). Perhaps it will take many years of vaccines like flu and flower vaccines.

Also, there are more than 100 types of cancer. **mRNA VACCINE** for cancer treatment is the new attractive field to treat cancer.



**The global pharma industry is set to grow by 3% to 6% per year and be worth over \$1.5 trillion by 2023, according to research from Report-linker.**

**PFIZER INC.** projected about \$15 billion in revenue this year from the Covid-19 vaccine it developed with BioNTech SE

Market value: \$96.1 billion. Dividend yield: 5.3%

**MODERNA** stock has rallied by over 75% since the beginning of 2021 and currently trades at levels of around \$185 per share, to over \$1.3 billion revenue in Q1 2021, The company has a market cap of \$52.36 billion

**PFIZER** stock \$38.90. Market value: \$214.7 billion. Dividend yield: 3.9%

**CUREVAC** stock \$118.40, Market Value: \$18 billion, then 2.25 billion euros in revenue

**ABBVIE** -Market value: \$174.9 billion. Dividend yield: 5.3%

**SANOFI**-Market value: \$128.2 billion. Dividend yield: 3.3%

**MERCK**-Market value: \$205.2 billion. Dividend yield: 3.0%

**AMGEN**-Market value: \$138.2 billion .Dividend yield: 2.7%

**NOVARTIS**-Market value: \$6.1 billion

**GLAXOSMITHKLINE**-Market value: \$96.1 billion, Dividend yield: 5.3%

**REGENERON PHARMACEUTICALS**-Market value: \$60.4 billion

**ALEXION PHARMACEUTICALS**-Market value: \$28.0 billion

**VERTEX Pharmaceuticals**-Market value: \$58.6 billion

**INCYTE**-Market value: \$18.1 billion

**ILLUMINA**-Market value: \$45.1 billion

**CRISPR Therapeutics**-Market value: \$18.1 billion

Thanks to its coronavirus-related efforts, shares of the biotech company are up by 524% over the past 12 months, **compared to gains of 15.5%** for the S&P 500

(This are information's from Kiplinger, Dana Blankenhorn, November 17, 2020)

The world needs technologies, facilities and investments that can produce hundreds of millions of vaccine doses that are cheaper and can be stored at room temperature.

Different vaccines will be produced to protect people. There are new projects in this context in America. They can be developed with investors. And investors still have time to act.

For project and investor communications [vaccinesheefa@gulfuscapital.com](mailto:vaccinesheefa@gulfuscapital.com)